Tips for Creating a Multidisciplinary Research Team Focused on Symptom Management

Catherine Bender, PhD, RN, FAAN, of the University of Pittsburgh, and Amy Hoffman, PhD, RN, of Michigan State University, shared their experiences in building interdisciplinary research teams to assess symptom management during a session at the 43rd Annual Congress in Washington, DC.

The Power of a Nurse: The Mara Mogensen Flaherty Memorial Lectureship

Margaret Bevans, PhD, RN, AOCN®, FAAN, program director and clinical nurse scientist at the National Institutes of Health’s Nursing Research and Translational Science department, detailed her own journey and empowered nurses to amplify their impact during her Mara Mogensen Flaherty Memorial lecture at the 43rd Annual Congress in Washington, DC.

Understanding Genomics and Using Precision Medicine to Advance Cancer Survival

During the American Association for Cancer Research/ONS Bench to Bedside session at the 43rd Annual Congress in Washington, DC, Victor Velculescu, MD, PhD, of Johns Hopkins University School of Medicine, and Maura Kadan, RN, MSN, of Personal Genome Diagnostics, dissected the science behind precision oncology, including an understanding of genetic alterations, the use of immunotherapy, and how to advance survival with these clinical breakthroughs.

Nurse-Led Initiatives Are Improving Patient Safety

During a session at the 43rd Annual Congress in Washington, DC, various speakers discussed the latest findings in patient safety.

How APRNs Can Impact Patient Outcomes Through Symptom Management

During a session at the 43rd Annual Congress in Washington, DC, various speakers discussed symptom management and supporting patient needs.

Managing Immunotherapy-Related Adverse Events

Immunotherapy is becoming an important role in cancer care and having an understanding of immune-related adverse events (irAEs) is critical for oncology nurses to provide safe and effective patient care. Rowena Schwartz, PharmD, BCOP, of the University of Cincinnati in Ohio, discussed strategies for managing these AEs during a session at the 43rd Annual Congress in Washington, DC.

Geographic Health Disparities Affect Access to Clinical Trials

Geographic location impacts life expectancy and even cancer care. Marylynn Ostrowski Ireland, PhD, of Viability, Inc., and Deborah Watkins Bruner, PhD, RN, FAAN, of Emory University in Atlanta, GA, discussed geographic health disparities during a session at the 43rd Annual Congress in Washington, DC.

Immunotherapy Opens New Frontiers in Lung Cancer Care

The development of targeted therapies brought new progress to lung cancer treatment and research in the past 20 years, and new options will continue to be available in the future. Roy Herbst, MD, PhD, director of thoracic oncology research program at the Yale Comprehensive Cancer Center at Yale School of Medicine in New Haven, CT, spoke at the 43rd Annual Congress in Washington, DC, on new standards of care for non-small cell lung cancer (NSCLC), immunotherapy for NSCLC, and development of rational drug combinations using biomarkers.

FDA Reports Efficacy Issue for Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1

fda

The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).

Opioids Are Not Always the Answer

As the opioid crisis continues in the United States, helping patients find effective and safer ways to manage their pain becomes increasingly important. During a session at the 43rd Annual Congress in Washington, DC, Jeannine Brant, PhD, APRN, AOCN®, FAAN, of Billings Clinic in Montana, instructed nurses on ways to treat cancer-related pain and discomforts other than (or in addition to) narcotic pain medicines.

Subscribe to